| Name | Title | Contact Details |
|---|
Welcome to LunchboxWax, a place that proves that chic and cheeky do, in fact, co-exist. Our refined, unique speed-waxing technique means smooth skin is just minutes away. You won`t be at LunchboxWax long, but while you`re here, you`ll feel like you`re the only one who matters. Because to us, you are. Great things happen when you choose to do one thing and do it well. That`s why we believe our Lunchbox waxologists are the best. They`re committed to their craft and your happiness. It`s all they do. Just like we handpick our waxologists, we assemble other experts to make our business run as smooth as your skin after a LunchboxWax Brazilian. Yep, we just said that. Our business formula works, and we`re excited to share it through the LunchboxWax Franchise System.
Official tweets from XANGO (Because tweeting officially is so much more pleasant than tweeting unofficially...!)
Celestiallabs Inc. is a Hoffman Estates, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clinical Laboratory Management is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.